Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CCRM accelerates the translation of regenerative medicine-based technologies—including cell and gene therapies—by providing strategic funding, infrastructure, business/scientific expertise, GMP-compliant manufacturing capabilities through its CDMO subsidiary OmniaBio Inc., and by launching or scaling new ventures. Its supported companies have raised over CA$1.2 billion collectively. Portfolio examples include ExCellThera (blood stem cell expansion) and Notch Therapeutics (T-cell therapies for cancer). The organization has built extensive infrastructure in Toronto’s MaRS Centre with CL2 labs and GMP suites.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CCRM.